Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CID-103 in Adults With Chronic Immune Thrombocytopenia
NCT07017725Phase 2Recruiting
- Sponsor
- CASI Pharmaceuticals, Inc.
- Start
- Jan 2025
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of CID-103 in immune thrombocytopenia (ITP), sponsored by CASI Pharmaceuticals, Inc.. Started Jan 2025; status: recruiting.
02
Drugs
CID-103
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT07017725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07017725.